- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02887248
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
Phase II Study of Nanoparticle Albumin-bound Paclitaxel Plus Gemcitabine as First-line Therapy for the Treatment of Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Fort Myers, Florida, United States, 33916
- Florida Cancer Specialists - South
-
Saint Petersburg, Florida, United States, 33705
- Florida Cancer Specialists-North
-
West Palm Beach, Florida, United States, 33401
- Florida Cancer Specialists-East
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Center for Cancer and Blood Disorders
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
KEY POINTS:
Inclusion Criteria:
- Histologically confirmed diagnosis of urothelial carcinoma (UC) that is either metastatic (any N+ M1) or locally advanced and unresectable (T4bN0). A component of urothelial (transitional cell) carcinoma is required.
Two groups of patients are eligible:
Poor candidates for cisplatin-based chemotherapy based on the presence of ≥ 1 the following:
- Glomerular filtration rate of 30-60 ml/min (Cockcroft-Gault formula)
- ECOG performance status score of 2
- Hearing loss (trouble communicating with hearing aids or hearing loss at ≤ 3 KHz)
- Grade ≥3 heart failure
- Age ≥80 years
- Other concurrent illness which may make the patient a poor candidate for receiving cisplatin.
Note: Enrollment of patients with 2 or more of these criteria should occur only after careful consideration by the treating physician regarding the patient's ability to tolerate combination chemotherapy.
OR
Poor prognosis and defined as cisplatin-incurable due to the presence of metastasis to at least one visceral site (these patients are not required to have any of the cisplatin-ineligibility criteria).
- ECOG performance status score of 0, 1, or 2.
- Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Patients with brain metastases are allowed if treatment was completed at least 4 weeks prior to study treatment, neurologic symptoms are minimal and stable during the preceding 4 weeks, and maintenance dexamethasone is not required.
- Adequate hematologic, liver and kidney function.
- Willingness and ability to comply with study requirements and give written informed consent.
Exclusion Criteria:
- Previous systemic chemotherapy for UC with the exception of perioperative (neoadjuvant or adjuvant) treatment or treatment with concurrent chemoradiation for locally advanced disease. All of these treatments must have been completed more than 1 year previously.
- Presence of small-cell or sarcomatoid component in tumor histology.
- Women who are pregnant or breast-feeding.
- Major surgical procedures ≤28 days of beginning study drug, or minor surgical procedures ≤7 days. No waiting required following port-a-cath placement.
- Cardiac diseases currently or within the last 6 months:
- Inadequately controlled hypertension.
- Currently receiving treatment with therapeutic doses of warfarin sodium. (A maximum daily dose of 1 mg will be permitted for port line patency. Low molecular weight heparin is allowed.)
- Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
- Known diagnosis of human immunodeficiency virus, hepatitis B or hepatitis C (screening for these diseases is not required.).
- Presence of other active cancers, or history of treatment for invasive cancer ≤5 years previously. Patients with Stage I cancer who have received definitive local treatment and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e., non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: nab-paclitaxel+gemcitabine
Induction Phase: nab-paclitaxel (125 mg/m²) and gemcitabine (1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle. Responding or stable patients will be treated with a minimum of 3 cycles and up to 6 cycles before starting the single agent maintenance therapy. Maintenance Phase: Patients completing 3-6 cycles of induction therapy with an objective response (complete or partial response) or stable disease will continue treatment with single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment. |
Induction: 125 mg/m² by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles to be given with Gemcitabine. Maintenance: single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment.
Other Names:
Induction: 1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
6 Month Progression-free Survival (PFS6)
Time Frame: up to 26 weeks
|
The percentage of treated patients who are progression-free at 6 months after start of treatment, assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Progressive disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest (nadir) sum since the treatment started, or the appearance of one or more new lesions.
Requires not only 20% increase, but absolute increase of a minimum of 5 mm over sum.
|
up to 26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate
Time Frame: every 3 cycles (9 weeks) until treatment discontinuation, an expected average of 1 year.
|
The proportion of patients with a confirmed complete or partial response (CR or PR) according to RECIST v1.1.
CR = disappearance of all target lesions.
PR = at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
|
every 3 cycles (9 weeks) until treatment discontinuation, an expected average of 1 year.
|
Clinical Benefit Rate
Time Frame: every 3 cycles (9 weeks) until treatment discontinuation, an expected average of 1 year.
|
Defined as the proportion of patients with CR, PR, or stable disease (SD) according to RECIST v1.1.
SD = neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest (nadir) sum of diameters since start of treatment.
|
every 3 cycles (9 weeks) until treatment discontinuation, an expected average of 1 year.
|
Overall Survival
Time Frame: every 9 weeks until disease progression or death on study, an expected average of 1 year. Patients with progressive disease will be followed every 3 months for the first year and every 6 months thereafter up to 5 years.
|
Defined as the time from Day 1 of study drug administration to disease progression or death on study.
|
every 9 weeks until disease progression or death on study, an expected average of 1 year. Patients with progressive disease will be followed every 3 months for the first year and every 6 months thereafter up to 5 years.
|
The Number of Participants With Grade 3/4/5 Adverse Events (AEs) as a Measure of Safety.
Time Frame: through study completion, an average of 1 year
|
The reported incidence of AEs with an onset on or after the initiation of therapy will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: John Hainsworth, MD, SCRI Development Innovations, LLC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Carcinoma
- Carcinoma, Transitional Cell
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Gemcitabine
Other Study ID Numbers
- SCRI GU 124
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Transitional Cell Carcinoma
-
Cliniques universitaires Saint-Luc- Université...NovartisTerminatedCarcinoma Transitional CellBelgium, Luxembourg
-
Associació per a la Recerca Oncologica, SpainUnknownUrothelium Transitional Cell CarcinomaSpain, Netherlands
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingTransitional Cell Carcinoma | Metastatic Urothelial Carcinoma | Unresectable Transitional Cell CarcinomaUnited States
-
UroGen Pharma Ltd.CompletedCarcinoma, Transitional Cell | Transitional Cell Carcinoma of Renal PelvisUnited States, Israel
-
Memorial Sloan Kettering Cancer CenterNovartisCompletedMetastatic Transitional Cell Carcinoma of the UrotheliumUnited States
-
Institute of Cancer Research, United KingdomCancer Research UKUnknownTransitional Cell Carcinoma of UreterUnited Kingdom
-
Shaheen AlaneeMerck Sharp & Dohme LLCUnknownEndoscopic Surgical Procedure | High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma | Transitional Epithelial CellsUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedTransitional Cell Carcinoma of Urinary TractNetherlands
-
Yale UniversityWithdrawnTransitional Cell CarcinomaUnited States
-
Chinese PLA General HospitalCompleted
Clinical Trials on nab-paclitaxel
-
Fudan UniversityActive, not recruitingTNBC - Triple-Negative Breast CancerChina
-
Shengjing HospitalRecruiting
-
M.D. Anderson Cancer CenterCelgene CorporationCompletedMelanoma | Liver MetastasisUnited States
-
HutchmedNot yet recruiting
-
Peking University Cancer Hospital & InstituteActive, not recruiting
-
Fundacion OncosurCompleted
-
Changhai HospitalRecruiting
-
Trishula Therapeutics, Inc.AbbVieRecruitingPancreatic CancerUnited States
-
CelgeneCompletedColorectal NeoplasmsFrance
-
AIO-Studien-gGmbHCelgene; ClinAssess GmbHCompletedResectable Pancreatic Cancer | Ductal Adenocarcinoma of the PancreasGermany